Phosphatidylethanol measures in patients with severe <scp>COVID</scp>‐19‐associated respiratory failure identify a subset with alcohol misuse
In a cohort of patients with severe COVID-19 enrolled in a clinical trial, alcohol consumption of two or more standard drinks per day was present among 21%, approximating the proportion of patients with diabetes, and raising the possibility that alcohol consumption alters risk for severe viral pneumonia. Undetected alcohol misuse among clinical trial participants has the potential to influence study outcomes or contribute to adverse events.
Authors
- Michael Owusu (ORCID: https://orcid.org/0000-0001-5066-150X)
- Sergio Melgar (ORCID: https://orcid.org/0000-0002-8785-0889)
- Ellen Lyda Burnham (ORCID: https://orcid.org/0000-0002-9945-0284)
- Sarah E. Jolley (ORCID: https://orcid.org/0000-0002-4616-7792)
- Raymond Pomponio (ORCID: https://orcid.org/0000-0003-0434-4751)
- Ryan Peterson (ORCID: https://orcid.org/0000-0002-4650-5798)
- Suzanne Slaughter
Institutions
- University of Denver (US)
- Colorado School of Public Health (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- Alcohol Clinical and Experimental Research
- Published
- 2024-11-26
- DOI
- https://doi.org/10.1111/acer.15495
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen Foundation
- Pfizer
- Takeda Pharmaceutical Company
- National Institutes of Health
- Defense Threat Reduction Agency
- Biomedical Advanced Research and Development Authority